hypogonadotropic hypogonadism

(redirected from secondary hypogonadism)

hypogonadism

 [hi″po-go´nad-izm]
decreased functional activity of the gonads, with retardation of growth, sexual development, and secondary sex characters. The American Association of Clinical Endocrinologists has published “Clinical Practice Guidelines for the Evaluation and Treatment of Hypogonadism in Adult Male Patients.” These are available online at their web site: http://www.aace.com.
hypergonadotropic hypogonadism that associated with secretion of high levels of gonadotropins, as in Klinefelter's syndrome. Called also hypergonadotropic eunuchoidism.
hypogonadotropic hypogonadism that due to lack of gonads or of gonadotropin secretion. Called also hypogonadotropic eunuchoidism.

hy·po·gon·a·do·trop·ic hy·po·go·nad·ism

[MIM*146110]
defective gonadal development or function, or both, resulting from inadequate secretion of pituitary gonadotropins.

hypogonadotropic hypogonadism

Hypogonadotropic eunuchoidism, Kallman syndrome A rare condition with a highly variable hereditary pattern, characterized by secondary hypogonadism–↓ gonadotropin-releasing hormone due to hypothalamic or pituitary dysfunction with testicular failure, and anosmia–due to hypoplasia or aplasia of the olfactory bulbs and tracts, 2º to a defect in the migration of olfactory neurons, and neurons producing GRH–gonadotropin-releasing hormone; ↓ FSH and LH impairs sperm and androgen production Clinical Delayed puberty, micropenis, eunuchoid features, cryptorchidism, midline defects–eg, cleft lip and palate, unilateral renal agenesis, horseshoe kidney, nerve deafness and hearing loss, color blindness, skeletal abnormalities; synkinesia, spatial attention defects, spastic paraplegia, cerebellar dysfunction, horizontal nystagmus, pes cavus, mental retardation Management Androgens to induce anatomic maturation; gonadotropins or LH-releasing factor for spermatogenesis. See Kalig-1.

hypogonadotropic hypogonadism

A usually congenital condition in which there is a severe deficiency of the gonadotropin-releasing hormone (GnRH) of the pituitary gland. As a rulethe penis remains infantile and the testes do not descend into the scrotum (cryptorchidism). No sexual development occurs at puberty. In rare cases the condition may develop in men who had previous normal secondary sexual development and a normal puberty. This leads to loss of libido, impotence and infertility. In these cases, treatment with gonadotropin-releasing hormone can reverse all the features of the disorder.
References in periodicals archive ?
Some years later, he read about clomiphene treatment for secondary hypogonadism, which might again substantially reduce his cost.
Secondary hypogonadism is pituitary or hypothalamic in origin.
M2 PHARMA-September 13, 2016-Repros Therapeutics submits accelerated marketing authorisation (MAA) for enclomiphene for secondary hypogonadism in Europe
M2 EQUITYBITES-September 13, 2016-Repros Therapeutics submits accelerated marketing authorisation (MAA) for enclomiphene for secondary hypogonadism in Europe
Checking free testosterone and prolactin levels can help identify which men with secondary hypogonadism should get brain MRIs.
CONCLUSION: Isolated adult onset secondary hypogonadism leading to testicular atrophy co-existing with central diabetes insipidus is a rare combination requiring a strong index of suspicion.
The most relevant forms of secondary hypogonadism are prolactinemia, which has several etiologies and thus a variable prevalence, and Kallmann syndrome, which affects 1 in 10 000.
There appear to be two separate tracks to primary hypogonadism marked by testicular dysfunction: secondary hypogonadism and compensated hypogonadism.
Fispemifene's product profile offers an exciting next-generation treatment option for men suffering from urological conditions such as secondary hypogonadism, in an existing multi-billion dollar market.
Human chorionic gonadotropin (HGC) is increased with germ cell tumors, which can be found in abdominal or testicular masses, resulting in secondary hypogonadism.
Patients were divided in to three groups according to the causes of hypogonadism: three patients with primary hypogonadism (12%), 15 patients with secondary hypogonadism (64%) and seven patients with pan- hypopituitarism) (24%).
The drug is being developed for the treatment of secondary hypogonadism, or a defect of the gonads that results in the underproduction of testosterone.

Full browser ?